Geoffrey Hamilton-Fairley’s entrepreneurial career started in 1982 by founding a number of companies in the media sector backed by The Abingdon Management Company Limited (Abingdon) – an institutional venture capital company. In 1988 he joined the board of Abingdon as CEO and subsequently became sole owner having acquired the company from its institutional shareholders. Abingdon had a number of quoted and unquoted investments in a variety of sectors; Property, Corporate Finance, Unit Trusts, an ITV franchise (TVS) and a few early technology companies – perhaps the mostnote worthy being Fortronic which developed the first magnetic strip plastic card swipe technology. In 1998 he launched Premium TV (PTV) securing a contractual joint venture with Eurosport to create “British Eurosport”. Later that year PTV was acquired by NTL (now Virgin Media). As CEO of PTV Geoffrey Hamilton-Fairley instigated and oversaw the highly complex development of the largest integrated broadband and internet sports broadcasting platform in the world (it still remain this today some 8 years later). Over the past ten years Mr Hamilton-Fairley has increasingly focussed his time and energies on the health sector. His family connections to medicine are strong and he enjoys combining his own scientific background as part of his role in enabling burgeoning science to become a reality. Geoffrey Hamilton-Fairley has dedicated almost all of his time in the past 5 years to the development of Oncimmune Ltd, serving as its Executive Chairman. The company has a unique technology for detecting the immune response to cancer at a very early stage in a cancer’s development – up to 4 years before current screening technologies. In addition to raising substantial funding for the Company, Geoffrey Hamilton-Fairley has guided it from its interesting laboratory results at Nottingham University to a successful commercial operation based in the USA backed by solid science. The tests success in its first year has led to a general belief that Oncimmune’s technology will soon play a significant role worldwide in improving prognosis for cancer sufferers.